Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)

INTRODUCTION: The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) has led to a change in the clinical management of breast cancer. Nausea and vomiting are the most common adverse events of T-DXd, which cannot be completely alleviated by standard prophylactic regimens. Olanzapine is particular...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Hitomi, Tsurutani, Junji, Ozaki, Yukinori, Ishiguro, Hiroshi, Nozawa, Kazuki, Watanabe, Kenichi, Maeda, Shigeto, Yokoe, Takamichi, Imamura, Chiyo K, Matsumoto, Koji, Iwasa, Tsutomu, Chiba, Yasutaka, Takiguchi, Daisuke, Takano, Toshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083740/
https://www.ncbi.nlm.nih.gov/pubmed/37012013
http://dx.doi.org/10.1136/bmjopen-2022-070304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083740/
https://www.ncbi.nlm.nih.gov/pubmed/37012013
http://dx.doi.org/10.1136/bmjopen-2022-070304

Ejemplares similares